U.S. markets close in 44 minutes
  • S&P 500

    3,995.38
    +53.90 (+1.37%)
     
  • Dow 30

    32,217.28
    +288.66 (+0.90%)
     
  • Nasdaq

    11,498.22
    +233.77 (+2.08%)
     
  • Russell 2000

    1,800.32
    +35.49 (+2.01%)
     
  • Crude Oil

    110.75
    +0.98 (+0.89%)
     
  • Gold

    1,853.20
    -12.20 (-0.65%)
     
  • Silver

    22.02
    -0.04 (-0.17%)
     
  • EUR/USD

    1.0689
    -0.0048 (-0.45%)
     
  • 10-Yr Bond

    2.7490
    -0.0110 (-0.40%)
     
  • GBP/USD

    1.2582
    +0.0050 (+0.40%)
     
  • USD/JPY

    127.3080
    +0.4790 (+0.38%)
     
  • BTC-USD

    29,850.69
    +608.72 (+2.08%)
     
  • CMC Crypto 200

    664.05
    -6.95 (-1.04%)
     
  • FTSE 100

    7,522.75
    +38.40 (+0.51%)
     
  • Nikkei 225

    26,677.80
    -70.34 (-0.26%)
     

Manhattan Scientifics Cancer Imaging Asset Announces Progress on Australian Clinical Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, November 01, 2021--(BUSINESS WIRE)--Manhattan Scientifics Inc. (OTC: QB), initially funded and is the current owner of more that 50 million shares of Imagion Biosystems Ltd. (IBX.AX).

Here we provide the reader with a televised interview with Imagion's CEO Bob Proulx. Stock Down Under Interview with Bob Proulx

About Manhattan Scientifics, Inc.
Manhattan Scientifics Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies. It has assisted incubating and financing closely with Science Teams at the Los Alamos National Laboratory and the Sandia National Laboratory in New Mexico

About Imagion Biosystems
Imagion Biosystems (www.imagionbiosystems.com)is developing a new non-radioactive and super-sensitive diagnostic imaging technology for very early detection of cancers. Imagion is listed on the Australian Stock Exchange (ASX).

Forward-looking statement
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005319/en/

Contacts

Manhattan Scientifics, Inc.
Manny Tsoupanarias, 917-688-4158
Manny@mhtx.com

Or
Marvin Maslow, 917-923-3300
Marvin@mhtx.com